The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
This highlights the importance of maintaining adequate glutathione levels for effective liver detoxification
Physical capacity, like the ability to climb stairs, walk distances, or complete workouts that were previously impossible
Semaglutide is a GLP-1 receptor agonist, while Tirzepatide is a dual GIP and GLP-1 receptor agonist
Doctors are doing their best but they are stuck playing defense battling prior authorizations, managing downstream effects and not the disease itself